Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
OBJECTIVE: This study sought to determine if relative neutropenia (RN) following six cycles of paclitaxel/carboplatin could serve as a prognostic factor in patients with ovarian cancer. DESIGN: A single institution, retrospective study. SETTING: Tertiary academic referral center, Seoul, Korea Population. A total of 179 patients who underwent primary cytoreductive surgery, followed by six cycles of paclitaxel/carboplatin chemotherapy to treat epithelial ovarian cancer. METHODS: Relative neutropenia was defined by an absolute neutrophil count < 1000 neutrophils/mm(3) at chemotherapy cycle nadir. To eliminate the effects of dose reduction (DR) and schedule delay (SD) on the outcome of analysis, 49 patients who had this were excluded, and a subset analysis of 130 patients who received standard doses and schedules of chemotherapy was performed. MAIN OUTCOME MEASURES: Progression free and overall survival. RESULTS: The median progression free survival (PFSs) of neutropenic and non-neutropeni
Related Questions
- Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation?
- Is eligibility for a chemotherapy protocol a good prognostic factor for invasive bladder cancer after radical cystectomy?
- Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor?
